Captrust Financial Advisors Mersana Therapeutics, Inc. Transaction History
Captrust Financial Advisors
- $43.1 Billion
- Q2 2025
A detailed history of Captrust Financial Advisors transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 41,746 shares of MRSN stock, worth $1.15 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
41,746
Previous 31,134
34.08%
Holding current value
$1.15 Million
Previous $10,000
20.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding MRSN
# of Institutions
40Shares Held
62.3MCall Options Held
34.3KPut Options Held
14K-
Nextech Invest Ag12.1MShares$331 Million3.22% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$230 Million0.0% of portfolio
-
Jacobs Levy Equity Management, Inc Florham Park, NJ1.33MShares$36.6 Million0.0% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC904KShares$24.8 Million0.64% of portfolio
-
Clari Vest Asset Management LLC San Diego, CA500KShares$13.7 Million0.09% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $2.67B
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...